Quantitative evaluation of CD52 expression in B-cell chronic lymphocytic leukemia

被引：1

作者：

D'Arena, G ^{[1
]}

Vigliotti, ML ^{[1
]}

Matera, R ^{[1
]}

Musto, C ^{[1
]}

Iodice, G ^{[1
]}

Tartarone, A ^{[1
]}

Di Renzo, N ^{[1
]}

机构：

[1] CROB Reg Hosp, Hematol Oncol Unit, Rionero In Vulture, Italy

来源：

LEUKEMIA & LYMPHOMA | 2003年 / 44卷 / 07期

关键词：

D O I：

10.1080/1042819031000076981

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1255 / 1257

页数：3

共 18 条

[1] PROPOSALS FOR THE CLASSIFICATION OF CHRONIC (MATURE) B-LYMPHOID AND T-LYMPHOID LEUKEMIAS [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

JOURNAL OF CLINICAL PATHOLOGY, 1989, 42 (06) :567-584

[2] Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H [J].

Birhiray, RE ;

Shaw, G ;

Guldan, S ;

Rudolf, D ;

Delmastro, D ;

Santabarbara, P ;

Brettman, L .

LEUKEMIA, 2002, 16 (05) :861-864

[3] Cell surface antigen and molecular targeting in the treatment of hematologic malignancies [J].

Countouriotis, A ;

Moore, TB ;

Sakamoto, KM .

STEM CELLS, 2002, 20 (03) :215-229

[4] Chronic lymphoproliferative disorders: An integrated point of view for the differential diagnosis [J].

D'Arena, G ;

Keating, MJ ;

Carotenuto, M .

LEUKEMIA & LYMPHOMA, 2000, 36 (3-4) :225-+

[5] Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density [J].

D'Arena, G ;

Dell 'Olio, M ;

Musto, P ;

Cascavilla, N ;

Perla, G ;

Savino, L ;

Greco, MM .

LEUKEMIA & LYMPHOMA, 2001, 42 (04) :649-654

[6]

D'Arena G, 2000, AM J HEMATOL, V64, P275

[7]

Davis KA, 1997, United States Patent, Patent No. 5620842

[8]

Dyer MJS, 1999, SEMIN ONCOL, V26, P52

[9] Levels of expression of CD52 in normal and leukemic B and T cells:: Correlation with in vivo therapeutic responses to Campath-1H [J].

Ginaldi, L ;

De Martinis, M ;

Matutes, E ;

Farahat, N ;

Morilla, R ;

Dyer, MJS ;

Catovsky, D .

LEUKEMIA RESEARCH, 1998, 22 (02) :185-191

[10] CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 [J].

Golay, J ;

Lazzari, M ;

Facchinetti, V ;

Bernasconi, S ;

Borleri, G ;

Barbui, T ;

Rambaldi, A ;

Introna, M .

BLOOD, 2001, 98 (12) :3383-3389

← 1 2 →